MENLO PARK, Calif.--(BUSINESS WIRE)--Sofinnova Investments, a biopharmaceutical investment firm, announced today the addition of Chris Carpenter, M.D., Ph.D., to the investment team as an Executive Partner.
Dr. Carpenter brings more than 20 years of clinical and operational experience, with a focus in oncology, rare diseases, and other specialty therapeutic areas. Before joining Sofinnova, he was Chief Medical Officer at Catamaran Bio. Previously, Dr. Carpenter was the Chief Medical Officer at Rubius Therapeutics, a company developing red blood cells as therapeutics.
Prior to Rubius, Dr. Carpenter was Senior Vice President and Head of the Cancer Epigenetics group at GlaxoSmithKline, where he was responsible for the overall strategy, as well as the identification and validation of new epigenetic targets and advancing novel therapies such as Votrient (pazopanib). Before GlaxoSmithKline, he was at Merck and led the development of MK-4827, which became Tesaro’s Zejula. Prior to Merck, Dr. Carpenter led a laboratory at Harvard Medical School and the Beth Israel Deaconess Medical Center for 14 years. He is board certified in internal medicine and medical oncology.
“I believe Chris will be an exceptional asset to our team and portfolio companies with his deep oncology and drug development expertise,” said Jim Healy, M.D., PhD., Managing Partner of Sofinnova Investments. “His breadth of knowledge and operational experience are valued across critical areas of our industry, from clinical-stage drug development through to large-scale commercialization experience, as well as operations.”
“I’m excited to join the Sofinnova Investments team, I look forward to applying my clinical development experience with the goal of advancing therapeutics for patients with unmet medical needs across Sofinnova’s portfolio,” said Dr. Carpenter.
Dr. Carpenter earned his B.S. from Stanford University, and received his M.D. and Ph.D. (pharmacology) degrees from the University of Southern California. He completed a residency in internal medicine at UT Southwestern, his hematology/oncology fellowship at Massachusetts General Hospital, and a post-doctoral fellowship in Lewis Cantley’s laboratory.
About Sofinnova Investments
Since 1976, Sofinnova has been active in life science investing. We are a biopharmaceutical investment firm with approximately $3.0B in assets under management and committed capital as of 12/31/21. We invest in both private and public equity of therapeutics-focused companies. Our goal is to actively partner with entrepreneurs in both the U.S. and Europe, across all stages of company formation. From drug development and navigating the regulatory process to company building and IPO, we strive to be collaborative, meaningful board members, and excellent partners at every level. We seek to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately, the lives of patients. For more information, please visit www.sofinnova.com.